(Adnkronos) – There is a red thread, a link between the self -employed cognitive decline and some blood biomarkers, which could open the way to a simple blood test to diagnose Alzheimer’s disease and related dementia. To identify it a team of scientists from the University of California San Diego School of Medicine, authors of a study that is part of the trend in full development of works aimed at making the diagnosis of this pathology as early as possible. The results of this last research, conducted on Hispanic and Latin adults, are published in the magazine ‘Jama Network Open’ and outlines an approach that could be “faster, less invasive and more convenient” than existing screening tools, explain the experts.
With the aging of the population and the numbers of patients affected by growing Alzheimer, it is a goal on which several groups are working. “We need methods to identify any neurodegenerative diseases in patients with cognitive symptoms early,” underlines the corresponding author of the study Freddie Márquez, post-dental researcher of the Department of Neuroscience of the Californian University. A promise can be represented by “blood -based biomarkers”, which are looming as a “most accessible and scalable tool to understand cognitive decline, in particular in the populations that have been scarcely treated with traditional methods”, reasoning Márquez.
Currently there is only one blood test approved by the Food and Drug Administration (FDA) to help diagnose Alzheimer’s disease. Although this test can detect the proteins in the blood associated with the disease that steals memories, it is currently “very expensive and available only in specialist assistance contexts”, illustrate experts. It is not yet clear whether the blood can be used reliablely for the early diagnosis of large -scale Alzheimer. To answer this question, the researchers used the data of a clinical study-‘Study of Latinos-Investment of Neurocognitive AGING’-which evaluated the neurocognition in a subgroup of participants in the wider and long-term long-term study on health and the pathologies of Hispanic and Latin American in the United States (the Hispanic Community Health Hispanic Community Study/Study of Latinos).
“It is believed that Hispanic and Latin adults will record the greatest increase in the prevalence of the disease in the next decades”, highlights the author Senior Hector M. González, professor of the UC neuroscience department of San Diego School of Medicine. “Nonetheless, they are still significantly under -representative in the research on Alzheimer’s and dementia, an aspect that our study proposed to face”.
The researchers analyzed the blood of 5,712 adults of this group, age between 50 and 86 years old, looking for proteins present in the brain of people with Alzheimer’s, such as Beta-Hamiloid and Tau. They also evaluated the subjective cognitive decline of the participants, that is, the decline perceived by the person himself. By putting these elements together, scientists discovered that higher blood levels of NFL (damage marker to nerve cells) and GFAP (brain marker) are associated with a greater decline – self -employed – thought, planning and overall cognitive performance. Higher blood levels of NFL and Tau protein (PTAU-181) have also been associated with a greater decline-self-employed-of memory. While the blood levels of the beta-amyloid protein (Aβ42/40), a protein notoriously associated in the brain of Alzheimer’s disease, have not shown association with subjective cognitive decline. Even in cognitively healthy people the associations between NFL and self -refined drops in cognitive services have remained valid, which – the experts evaluate – suggests that NFL could detect early changes in cognition.
In addition to providing evidence of the fact that blood biomarkers can be used to detect alzheimer’s and dementias early, researchers also underline that a strong point of study is its heterogeneous population. “Including participants from under -representative communities, we are able to better understand how the social determinants of health and comorbilities can influence cognitive paths and the risk of dementia,” adds Márquez. “This makes our results particularly relevant for the contexts of the real world”. Further research will now be needed – they would like to point out the authors – before this approach finds wide diffusion in clinical practice and, even when this happens, the test will still be one of the tools in the doctor’s diagnostic arsenal. “It is important to emphasize that there is still much that we do not know about the usefulness of blood biomarkers for the diagnosis of Alzheimer’s”, concludes Márquez. “These tests have enormous potential, but they should integrate existing approaches, not to replace them.”
Blood Biomarkers and Alzheimer’s: Key Findings
Table of Contents
This research, conducted by scientists at the university of California San diego School of Medicine, offers promising advancements in the early detection of alzheimer’s disease and related dementias. By analyzing blood biomarkers, researchers have identified potential indicators of cognitive decline, paving the way for less invasive and more accessible diagnostic tools. The study, published in the journal ‘Jama Network Open,’ focused on Hispanic and Latin adults, a population projected to experiance a significant increase in Alzheimer’s prevalence in the coming decades. This research underscores the importance of diverse representation in Alzheimer’s research and the potential of blood-based biomarkers to revolutionize early detection.
Key Findings at a Glance:
| Biomarker | Association | Cognitive Domains Affected | Significance |
| :————————————— | :——————————————————————————————————————————————– | :——————————— | :————————————————————————————————————————————- |
| NFL (Neurofilament Light chain) | Higher blood levels associated with greater self-reported cognitive decline. | Thought, Planning, Overall Cognition | Potential for early detection of cognitive changes, even in cognitively healthy individuals. |
| GFAP (Glial Fibrillary Acidic Protein) | Higher blood levels associated with greater self-reported cognitive decline. | Thought, Planning, Overall Cognition | Indicates brain injury, potentially linked to early cognitive decline and should be monitored . |
| PTAU-181 (Phosphorylated Tau Protein) | Higher blood levels associated with greater self-reported memory decline. | Memory | Provides deeper insight into specific aspects of the decline, especially memory function. |
| Aβ42/40 (Beta-amyloid Protein) | No significant association found with subjective cognitive decline. | – | Suggests the complexity of the disease’s various stages. Beta-amyloid presence may not trigger cognitive decline immediately. |
Table data is taken from the referenced study.
A New Era in Alzheimer’s Diagnostics
The use of blood-based biomarkers in the diagnosis of Alzheimer’s is still in its early stages,and more research and analyses are needed to further cement thier effectiveness,but the latest research indicates that these biomarkers may be effective in detecting Alzheimer’s disease up to 16 years before the onset of any symptoms[[1]]. This could lead to early interventions and improved patient outcomes. Using blood tests for diagnosis will accelerate both the actual diagnosis and access to available treatments[[2]]. Blood tests could become the standard of care in the future[[3]].
Frequently Asked Questions (FAQ)
Here are some common questions about Alzheimer’s disease and the role of blood biomarkers,along with clear and concise answers:
Q: What are blood biomarkers for alzheimer’s disease?
A: Blood biomarkers are specific substances in the blood that can indicate the presence or progression of Alzheimer’s disease. These biomarkers include proteins like NFL, GFAP, and Tau which are analyzed to assess the status of the individual’s cognitive health and memory.
Q: How are blood biomarkers different from conventional Alzheimer’s diagnostic methods?
A: Unlike traditional methods like brain scans (e.g., PET scans) and spinal taps, blood tests are less invasive, more accessible, and potentially more cost-effective, creating a better path to receive a diagnosis. Blood test results can be delivered in a faster time which creates a better path to treatment.
Q: What do the results of a blood biomarker test mean?
A: The results of a blood biomarker test can provide insights into the presence of Alzheimer’s-related proteins in the blood, and the patient’s risk of cognitive decline. Elevated levels of certain biomarkers may suggest early cognitive changes or an increased risk of developing Alzheimer’s disease.
Q: Are blood tests for alzheimer’s widely available now?
A: While promising, these tests are still primarily used in research settings. Though, the increased availability and potential impacts on the medical field are creating positive impacts on the health care industry. The first FDA-approved blood test for Alzheimer’s is already available, and more tests are anticipated in the coming years.
Q: Can blood tests definitively diagnose Alzheimer’s disease?
A: Currently,blood tests are not designed to be a standalone diagnostic tool. They are most effective when used alongside other diagnostic methods, such as cognitive assessments and medical history, to provide a comprehensive picture of an individual’s cognitive health.
Q: Who should consider getting a blood test for Alzheimer’s?
A: Individuals who are experiencing early symptoms of cognitive decline such as memory loss, confusion, or changes in their thinking. also, people with a family history of Alzheimer’s disease or are considered to be at higher-risk individuals.
Q: How early can blood biomarkers detect Alzheimer’s disease?
A: According to recent studies, blood biomarkers can potentially detect changes associated with Alzheimer’s several years before the onset of noticeable symptoms[[1]].
Q: What are the advantages of using blood tests for Alzheimer’s diagnosis?
A: Blood tests offer a faster and more accessible way to assess the risk of Alzheimer’s disease. They are less invasive than other methods, which increases comfort, makes it more convenient, and creates a better access to early interventions.
Q: What are the risks associated with blood biomarker testing?
A: The risks are minimal, but the results may cause anxiety while waiting for the diagnosis. It is indeed essential to consult with a healthcare professional to fully understand the test results and next steps.
